136 research outputs found
A new bifunctional catalyst for tandem Heck-asymmetric dihydroxylation of olefins
A new bifunctional catalyst consisting of active palladium and osmium species anchored on silica gel through a mercaptopropyl spacer and a cinchona alkaloid respectively has been prepared for the first time and used in the heterogeneous tandem Heck-asymmetric dihydroxylation of olefins to afford diols with excellent yields and enantiomeric excesses (ee's) in presence of N-methylmorpholine Noxide or K3Fe(CN)6 as cooxidants
The first example of direct oxidation of sulfides to sulfones by an osmate molecular oxygen system
Osmate-exchanged Mg-Al layered double hydroxides catalysed the delivery of two oxygen atoms simultaneously via a 3 + 1 cycloaddition to sulfide to form sulfone directly for the first time, reminiscent of 3 + 2 cycloaddition in asymmetric dihydroxylation reactions
Clinical and Histological Comparison of Extraction Socket Healing Following the Use of Autologous Platelet-Rich Fibrin Matrix (PRFM) to Ridge Preservation Procedures Employing Demineralized Freeze Dried Bone Allograft Material and Membrane
Gut mucosal DAMPs in IBD: From mechanisms to therapeutic implications
Endogenous damage-associated molecular patterns (DAMPs) are released during tissue damage and have increasingly recognized roles in the etiology of many human diseases. The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease (CD), are immune-mediated conditions where high levels of DAMPs are observed. DAMPs such as calprotectin (S100A8/9) have an established clinical role as a biomarker in IBD. In this review, we use IBD as an archetypal common chronic inflammatory disease to focus on the conceptual and evidential importance of DAMPs in pathogenesis and why DAMPs represent an entirely new class of targets for clinical translation. </p
The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature
Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary
There has been considerable investigation of the potential for soyfoods to reduce risk of cancer, and in particular cancer of the breast. Most interest in this relationship is because soyfoods are essentially a unique dietary source of isoflavones, compounds which bind to estrogen receptors and exhibit weak estrogen-like effects under certain experimental conditions. In recent years the relationship between soyfoods and breast cancer has become controversial because of concerns – based mostly on in vitro and rodent data – that isoflavones may stimulate the growth of existing estrogen-sensitive breast tumors. This controversy carries considerable public health significance because of the increasing popularity of soyfoods and the commercial availability of isoflavone supplements. In this analysis and commentary we attempt to outline current concerns regarding the estrogen-like effects of isoflavones in the breast focusing primarily on the clinical trial data and place these concerns in the context of recent evidence regarding estrogen therapy use in postmenopausal women. Overall, there is little clinical evidence to suggest that isoflavones will increase breast cancer risk in healthy women or worsen the prognosis of breast cancer patients. Although relatively limited research has been conducted, and the clinical trials often involved small numbers of subjects, there is no evidence that isoflavone intake increases breast tissue density in pre- or postmenopausal women or increases breast cell proliferation in postmenopausal women with or without a history of breast cancer. The epidemiologic data are generally consistent with the clinical data, showing no indication of increased risk. Furthermore, these clinical and epidemiologic data are consistent with what appears to be a low overall breast cancer risk associated with pharmacologic unopposed estrogen exposure in postmenopausal women. While more research is required to definitively allay concerns, the existing data should provide some degree of assurance that isoflavone exposure at levels consistent with historical Asian soyfood intake does not result in adverse stimulatory effects on breast tissue
Analysis of the human monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new insights into genetic aetiology of inflammatory bowel disease
The FANTOM5 consortium utilised cap analysis of gene expression (CAGE) to provide an unprecedented insight into transcriptional regulation in human cells and tissues. In the current study, we have used CAGE-based transcriptional profiling on an extended dense time course of the response of human monocyte-derived macrophages grown in macrophage colony-stimulating factor (CSF1) to bacterial lipopolysaccharide (LPS). We propose that this system provides a model for the differentiation and adaptation of monocytes entering the intestinal lamina propria. The response to LPS is shown to be a cascade of successive waves of transient gene expression extending over at least 48 hours, with hundreds of positive and negative regulatory loops. Promoter analysis using motif activity response analysis (MARA) identified some of the transcription factors likely to be responsible for the temporal profile of transcriptional activation. Each LPS-inducible locus was associated with multiple inducible enhancers, and in each case, transient eRNA transcription at multiple sites detected by CAGE preceded the appearance of promoter-associated transcripts. LPS-inducible long non-coding RNAs were commonly associated with clusters of inducible enhancers. We used these data to re-examine the hundreds of loci associated with susceptibility to inflammatory bowel disease (IBD) in genome-wide association studies. Loci associated with IBD were strongly and specifically (relative to rheumatoid arthritis and unrelated traits) enriched for promoters that were regulated in monocyte differentiation or activation. Amongst previously-identified IBD susceptibility loci, the vast majority contained at least one promoter that was regulated in CSF1-dependent monocyte-macrophage transitions and/or in response to LPS. On this basis, we concluded that IBD loci are strongly-enriched for monocyte-specific genes, and identified at least 134 additional candidate genes associated with IBD susceptibility from reanalysis of published GWA studies. We propose that dysregulation of monocyte adaptation to the environment of the gastrointestinal mucosa is the key process leading to inflammatory bowel disease
ECLAPTE: Effective Closure of LAParoTomy in Emergency-2023 World Society of Emergency Surgery guidelines for the closure of laparotomy in emergency settings
Laparotomy incisions provide easy and rapid access to the peritoneal cavity in case of emergency surgery. Incisional hernia (IH) is a late manifestation of the failure of abdominal wall closure and represents frequent complication of any abdominal incision: IHs can cause pain and discomfort to the patients but also clinical serious sequelae like bowel obstruction, incarceration, strangulation, and necessity of reoperation. Previous guidelines and indications in the literature consider elective settings and evidence about laparotomy closure in emergency settings is lacking. This paper aims to present the World Society of Emergency Surgery (WSES) project called ECLAPTE (Effective Closure of LAParoTomy in Emergency): the final manuscript includes guidelines on the closure of emergency laparotomy
Mitochondrial damage-associated molecular patterns (DAMPs) in inflammatory bowel disease
Background
The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn’s
disease (CD) are chronic relapsing inflammatory disorders which have a rising
incidence and cause significant morbidity. There are currently several
treatment options with many more in the drug pipeline, but there are a lack of
accurate biomarkers for decisions on treatment choice, assessment of disease
activity and prognostication. There is a growing interest and desire for
personalised or ‘precision’ medicine in IBD where novel biomarkers may help
individualise IBD care in terms of diagnosis, choice of therapy, monitoring of
response and detection of relapse. One class of functionally active biomarkers
which have yet to be thoroughly investigated in IBD is damage-associated
molecular patterns (DAMPs) including mitochondrial DNA (mtDNA). It has
been recently shown that gut mitochondrial dysfunction can result in loss of
epithelial barrier function and the development of colitis. Mitochondrial DAMPs
have recently been described as elevated in several inflammatory diseases.
Hypothesis
The primary hypothesis of this thesis is that circulating levels of mtDNA is
elevated in IBD. Secondary hypotheses are: (a) levels of other mitochondrial
DAMPs are elevated in IBD, (b) circulating mtDNA can be used as a novel
biomarker in IBD and (c) mtDNA is released locally at sites of inflammation in
IBD.
Methods
Plasma and serum were collected prospectively from recruited IBD patients
and non-IBD controls. Faeces and colonic tissue were collected from a subset
of these patients. mtDNA in serum, plasma and faeces was measured using
qPCR (amplifying COXIII/ND2 genes). Mass spectrometry was used to detect
mitochondrial formylated peptides in the plasma of a subset of patients. IBD
tissue was assessed for (a) mitochondrial damage using transmission electron
microscopy (TEM) and (b) TLR9 expression, the target for mtDNA.
Results
97 patients with IBD (67 UC and 30 CD), and 40 non-IBD controls were
recruited. Plasma mtDNA levels were increased in UC and CD (both p<0.0001)
compared to non-IBD controls; with significant correlations with blood (CRP,
albumin, white cell count), clinical and endoscopic markers of severity; and
disease activity. In active UC, we detected significantly higher circulating
mitochondrial formylated peptides and faecal mtDNA levels (vs. non-IBD
controls [p<0.01 and <0.0001 respectively]) with demonstrable TEM evidence
of intestinal mucosal mitochondrial damage. In active IBD, TLR9+ lamina
propria inflammatory cells were significantly higher in UC/CD compared to
controls (both p<0.05).
Conclusions
Taken together, the findings suggest mtDNA is released during active
inflammation in inflammatory bowel disease and is a potential novel
mechanistic biomarker
- …